CanSinoBIO's inhaled COVID booster stronger vs Omicron's BA.1 than Sinovac shot | Inquirer News

CanSinoBIO’s inhaled COVID booster stronger vs Omicron’s BA.1 than Sinovac shot

/ 03:05 PM July 29, 2022
CanSino Biologic's inhalation-based candidate vaccine shows a better antibody response as a booster against the BA.1 Omicron sub-variant than Sinovac's shot

FILE PHOTO: A logo of China’s vaccine specialist CanSino Biologics Inc is pictured on the company’s headquarters in Tianjin, following an outbreak of the coronavirus disease (COVID-19), China on August 17, 2020. REUTERS/Thomas Peter

BEIJING — Chinese vaccine firm CanSino Biologic’s inhalation-based candidate elicited a better antibody response as a booster against the BA.1 Omicron sub-variant than Sinovac’s shot, but the antibody level dropped in months, clinical trial data showed.

The result came as top political leaders in China called for proper tracking of virus mutation and the development of new vaccines and treatments in the country’s effort to refine its COVID control strategy.

ADVERTISEMENT

China has given about 56% of its 1.41 billion population a booster dose using domestic shots, and most people were boosted with the same product as their primary series, despite growing evidence that some mix-and-max strategies would likely achieve higher antibody levels.

Among over 100 adults who received a lower dose of CanSinoBIO’s inhaled vaccine candidate following two Sinovac shots, after four weeks, 92.5% developed the neutralizing antibody that neutralizes Omicron at levels that researchers defined as detectable, according to a paper published without peer review.

FEATURED STORIES

That compared with 88.9% for a higher-dose group, also with over 100 participants, said in a paper published late on Thursday.

The rate for both groups declined to around 70% after six months of the inhaled booster.

Barely any of the over 100 participants who received a third Sinovac shot had detectable neutralizing antibody for Omicron after four weeks or six months.

The study did not compare CanSinoBIO’s inhaled booster with other potential boosters that have triggered stronger antibody responses than a third dose of the Sinopharm or Sinovac shot.

Antibody-based readings reflect an important part of the vaccine-triggered immune response and are different from the vaccine efficacy that indicates how well a shot reduces the risk of COVID disease, hospitalization, or death.

The impact of BA.4 and BA.5 Omicron sub-variants on CanSinoBIO’s inhaled vaccine deserves further study, said the authors, who worked at CanSinoBIO and other Chinese institutes.

CanSinoBIO’s experimental inhaled vaccine uses a technology similar to that of its injection-based shot, which has been approved in countries including China, Mexico, and Argentina, and AstraZeneca’s vaccine.

ADVERTISEMENT

The company is also testing a candidate based on the mRNA method in a mid-stage clinical trial in China.

RELATED STORY

Omicron-specific Sinopharm, Sinovac vaccine candidates cleared for clinical trial

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: BA.1, booster, CanSino, China, COVID-19, Omicron, Sinovac, vaccine
For feedback, complaints, or inquiries, contact us.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.



© Copyright 1997-2023 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.